GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma
- Research demonstrates that E-selectin ligand in myeloma confers more aggressive disease and greater resistance to bortezomib (standard of care)
- GMI-1271 was able to restore sensitivity to bortezomib
E-selectin ligands are recognized by an antibody known as HECA452. In this manuscript, researchers described that E-selectin ligands expressed on myeloma cell surfaces and recognized by HECA452 induced a more aggressive form of multiple myeloma, which is insensitive to bortezomib. Through use of GMI-1271, sensitivity to the proteasome inhibitor therapy, bortezomib, was able to be restored in this highly resistant myeloma model.
"The results in this preclinical study demonstrate that targeting
E-selectin may provide a novel approach to treatment of patients with
multiple myeloma and could potentially restore sensitivity to
chemotherapy and, in particular, proteasome inhibitor therapy," said
"We look forward to presenting an update on our AML clinical trial at
the ASCO Annual Meeting and to sharing what is known so far about
E-selectin ligand expression in the context of that trial," said
About Multiple Myeloma
Multiple myeloma is an incurable form of blood cancer where the plasma cells in the bone marrow grow uncontrollably and may not function well while other blood forming cells (e.g., white/red blood cells and blood platelets) are suppressed. Normal plasma cells are an important part of the body's immune defense and play a critical role in the production of antibodies. Multiple myeloma can therefore lead to infections, anemia, destruction of bone tissue and kidney problems. While some advances have been made in treatment, there remains a large unmet medical need for patients with multiple myeloma.
About GMI-1271
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug's potential role in blocking E-selectin-mediated chemo-resistance pathways as well as moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy.
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
iE-selectin
ligands recognised by HECA452 induce drug resistance in myeloma, which
is overcome by the E-selectin antagonist, GMI-1271. Natoni A, Smith
TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E,
Raab MS, Glavey SV,
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005831/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media